KARAKTERISTIK KARSINOMA PARU BUKAN SEL KECIL DAN HASIL PEMERIKSAAN EGFR DI RSUP DR. HASAN SADIKIN PERIODE TAHUN 2018-2020

  • Teja Koswara Departemen Patologi Anatomi, Fakultas Kedokteran, Universitas Jenderal Achmad Yani, Cimahi. Indonesia
  • Jusron Iriawan 2Departemen Ilmu Penyakit Dalam, Fakultas Kedokteran, Universitas Jenderal Achmad Yani, Cimahi. Indonesia
  • Fiona Surya Departemen Patologi Anatomi, Fakultas Kedokteran, Universitas Jenderal Achmad Yani, Cimahi. Indonesia

Abstract

Karsinoma paru adalah keganasan akibat pertumbuhan baru dari sel epitel paru yang abnormal. Karsinoma paru diklasifikasikan menjadi dua tipe; Kanker Paru Karsinoma Bukan Sel Kecil dan Kanker Paru Karsinoma Sel Kecil. Tipe KPKBSK ditemukan sebanyak 85% dari kasus karsinoma paru. Pada KPKBSK sering ditemukan overekspresi EGFR. Tujuan penelitian ini untuk mengetahui karakteristik pasien, status merokok, status fungsional, stadium klinis, diagnosis histopatologi, dan hasil pemeriksaan EGFR dari KPKBSK di RSUP Dr. Hasan Sadikin Bandung periode tahun 2018-2020. Penelitian ini merupakan penelitian deskriptif dengan subjek penelitian rekam medis pasien yang didiagnosis KPKBSK. Data diambil dengan metode total sampling. Dari 67 kasus KPKBSK, pasien KPKBSK paling banyak ditemukan pada kelompok usia 55-64 tahun (31,3%). Jenis kelamin terbanyak adalah laki laki (62,7%). KPKBSK lebih banyak didapatkan pada pasien bukan perokok (83,6%). Status fungsional dari pasien KPKBSK yang terbanyak adalah “sangat tergantung” (46,3%). Stadium klinis pasien KPKBSK yang terbanyak adalah stadium IV (97%). Diagnosis histopatologi KPKBSK yang terbanyak adalah adenokarsinoma (67,2%). Sebagian besar penderita KPKBSK di RSUP Dr. Hasan Sadikin Bandung tidak menjalani pemeriksaan EGFR (80,6%). Pasien yang dilakukan pemeriksaan EGFR hasil yang terbanyak adalah negatif (9%). Subtipe tumor dengan hasil pemeriksaan EGFR yang positif dan negatif seluruhnya adalah subtipe adenokarsinoma. Simpulan dari penelitian ini, karakteristik KPKBSK adalah usia 55-64 tahun, jenis kelamin laki-laki, bukan perokok, status fungsional pasien “sangat tergantung”, stadium klinis IV, diagnosis histopatologi adenokarsinoma, dan hasil pemeriksaan EGFR negatif. Overekspresi EGFR pada KPKBSK terjadi akibat mutasi somatik pada domain tirosin kinase menyebabkan transduksi sinyal dan proses fosforilasi yang terus menerus.


 


DOI : 10.35990/mk.v5n2.p150-161

References

1. Kumar V, Abbas AK, Aster JC. Buku Ajar Patologi Robbins. Edisi 9. Singapura: Elsevier Saunders; 2015. hal. 155-156, 167, 204.
2. Siddiqui F, Siddiqui AH. Lung Cancer. https://www.ncbi.nlm.nih.gov/books/N BK482357/ (November 2020) [accessed June 4th 2021].
3. Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, et al. Global Cancer Observatory: Cancer Today. Lyon: International Agency for Research on Cancer.
https://gco.iarc.fr/today. 2020.
[accessed April 2021].
4. Dorland. Kamus Kedokteran Dorland. Edisi 29. Jakarta: EGC;2015. hal. 127.
5. Kementerian Kesehatan Republik Indonesia. Inilah Faktor Risiko Penyebab Karsinoma Paru. http://www.p2ptm.kemkes.go.id/infogr aphic-p2ptm/penyakit-karsinoma-dan-

kelainan-darah/inilah-faktor-risiko-pen yebab-karsinoma-paru 8 Feb 2021. (8
Februari 2021) [Diunduh tanggal 9
April 2021].
6. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. American Cancer Society Journals 2021;0: 1-41.
7. Aliyah N, Pranggono EH, Andriyoko
B. Karsinoma Paru: Sebuah Kajian Singkat. Indonesia Journal CHEST Crit and Emerg Med 2016;4(1): 28-32.
8. Kementerian Kesehatan Republik Indonesia. Pedoman Nasional Pelayanan Kedokteran Karsinoma Paru. Indonesia. 2017.
9. Zappa C, Mousa S. Non-Small Cell Lung Cancer: Current Treatment and Future Advances. Translational Lung Cancer Research 2016;5(3): 288-300.

10. American Lung Association. Lung Cancer Basics. Chicago. 2021.
11. Cancer Research UK. Lung Cancer: Survival. https://www.cancerresearchuk.org/abo ut-cancer/lung-cancer/survival. (23 September 2020). [accessed July 23rd 2021].
12. Morgan K. Your Chances of Surviving Lung Cancer.
https://www.webmd.com/lung-cancer/ guide/lung-cancer-survival-rates. (30 September 2019) [accessed July 23rd 2021].
13. Alghamdi HI, Alshehri AF, Farhat GN. An Overview of Mortality & Predictors of Small-Cell and Non-Small Lung Cancer Among Saudi Patients. Journal of Epidemiology and Global Health 2018;7: 51-56.
14. Soetandyo N, et al. Prognosis of Advanced Stage Non-Small-Cell Lung Cancer Patients Receiving Chemotherapy: Adenocarcinoma Versus Squamous Cell Carcinoma. Medical Journal of Indonesia 2020;29(1): 26-31.
15. Putra DN, W Laksmi, Mustokoweni S. Profil Penderita Karsinoma Paru Karsinoma Bukan Sel Kecil (KPKBSK) Di RSUD Dr. Soetomo. Jurnal Ilmiah Mahasiswa Kedokteran Universitas Airlangga 2016;8(1): 30-34.
16. Okamoto I, et al. Real World Treatment And Outcomes In EGFR Mutation-Positive Non-Small Cell Lung Cancer: Long-Term Follow-Up of A Large Patient Cohort. Elsevier: Lung Cancer 2018;117: 14-19.
17. Wulandari F, Utami W, Rohana E, Prabhata WR. Efikasi Terapi Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKIs) pada Karsinoma Paru.

Generics: Journal of Research in Pharmacy 2021;1(1): 25-27.
18. Salimath S, Jayaraj BS, Mahesh PA. Epidermal Growth Factor Receptor (EGFR) Expression in Non-Small Cell Lung Carcinoma (KPKBSK) and Survival. European Respiratory Journal 2015; 46 (suppl 59).
19. Wulandari L. Mutasi Epidermal Growth Factor Receptor. http://news.unair.ac.id/2020/05/10/mut asi-epidermal-growth-factor-receptor/. (10 Mei 2020). [Diakses tanggal 16 April 2021].
20. Cancer.Net. Lung Cancer- Non-Small Cell: Statistics.
https://www.cancer.net/cancer-types/lu ng-cancer-non-small-cell/statistics (January 2021) [accessed June 1st 2020].
21. Han B, et al. EGFR Mutation Prevalence in Asia-Pacific and Russian Patients with Advanced KPKBSK of Adenocarcinoma and Non-Adenocarcinoma Histology: The IGNITE Study. Elsevier: Lung Cancer 2017;113: 37-44.
22. Rajabto W, Angkasa YK. Mutasi EGFR sebagai Faktor Prediktif Respons Pengobatan terhadap TKI (Tyrosine Kinase Inhibitor) pada Non-Small Cell Lung Cancer Stadium 4: Sebuah Laporan Kasus. Jurnal Penyakit Dalam Indonesia 2021;8(1): 43-45.
23. Gkogkou P., et al. E-Cadherin and Syndecan-1 Expression in Patients with Advanced Non-small Cell Lung Cancer Treated with Chemoradiotherapy. In Vivo 2020;34(1): 453-459.
24. Shu-Chen D., et al. Glutathione S-transferase π: a potential role in antitumor therapy. Drug Design,

Development and Therapy 2018;12: 3535–3547.
25. Lara V.R, et al. Influence of Estrogen in Non-Small Cell Lung Cancer and Its Clinical Implications. Journal of Thoracic Disease 2018;10(1): 482-497.
26. N.U. Din Shah, et al. Association of Promoter Methylation of RASSF1A and KRAS Mutations in Non-Small Cell Lung Carcinoma in Kashmiri Population (India). Heliyon 2020;6: 1-9.
27. Putriani F.A, et al. Perbedaan Faktor Risiko Penderita Adenokarsinoma Paru dengan Mutasi EGFR dan Non Mutasi EGFR. Jurnal Kedokteran Diponegoro 2019;8(1): 214-221.
28. Roman M., et al. KRAS Oncogene in Non-Small Cell Lung Cancer: Clinical Perspectives on The Treatment of an Old Target. Molecular Cancer 2018;17(33): 1-14.
29. Tan W., et al. Non-Small Cell Lung Cancer (NSCLC).
https://emedicine.medscape.com/articl e/279960-overview#a4 (September 2021) [accessed December 30th 2021].
30. Smolle E, Pichler M. Non-Smoking-Associated Lung Cancer: A Distinct Entity in Terms of Tumor Biology, Patient Characteristics and Impact of Hereditary Cancer Predisposition. Cancers 2019;11(204): 1-13.
31. Wee P, Wang Z. Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways. Cancers 2017;9(52): 1-45.
32. Riesco A, et al. Epidermal Growth Factor Signaling towards Proliferation: Modeling and Logic Inference Using Forward and Backward Search. https://www.hindawi.com/journals/bmr

i/2017/1809513/ (16 January 2017) [accessed July 12th 2021].
33. Asrul HH. Hubungan Berbagai Karakteristik Penderita Adenokarsinoma Paru Dengan Status Mutasi Epidermal Growth Factor Receptor (EGFR) di RSUP Haji Adam Malik Medan Tahun 2015-2017. Medan: Fakultas Kedokteran Universitas Sumatera Utara. 2018.
34. Tseng CH, et al. EGFR Mutation, Smoking, and Gender in Advanced Lung Adenocarcinoma. Impact Journals: Oncotarget 2017;8(58): 98384-98393.
35. Ahyati SN, Oktaviyanti IK, Yuliana I. Hubungan Jenis Kelamin dan Riwayat Merokok dengan Mutasi Gen EGFR Karsinoma Paru Tipe Adenokarsinoma.
Homeostasis 2019;2(1): 1-8.
36. Laily LL, Martini S, Artanti KD, Widati S. Risk Factors of Lung Adenocarcinoma in Patients at Dr. Soetomo District General Hospital Surabaya in 2018. The Indonesian Journal Public Health 2020;15(3): 295-303.
37. Reynaldi A, et al. Kualitas Hidup Pasien Kanker Paru Stadium Lanjut. JNC 2020;3(2): 71-78.
38. Neo J, et al. Disability in Activities of Daily Living Among Adults With Cancer: A Systematic Review and Meta-Analysis. Elsevier: Cancer Treatment Reviews 2017;94-106.
39. Gridelli C, et al. Chemotherapy for Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Multicenter Italian Lung Cancer in the Elderly Study (MILES) Phase III Randomized Trial. Journal of the National Cancer Institute 2013; 95(5): 362-372

40. Maione P, et al. Pretreatment Quality of Life and Functional Status Assessment Significantly Predict Survival of Elderly Patients with Advanced Non—Small-Cell Lung Cancer Receiving Chemotherapy: A Prognostic Analysis of the Multicenter Italian Lung Cancer in the Elderly Study. Journal of Clinical Oncology 2016;23(2 8): 6865-6872.
41. Tobacco Control Support Center-Ikatan Ahli Kesehatan Masyarakat Indonesia. Atlas Tembakau Indonesia 2020. Indonesia. 2020.
42. Cancer Research UK. Why is Early Diagnosis Important? England and Wales. 2021.
43. Markman M. What is Stage 4 Lung Cancer? https://www.cancercenter.com/cancer-t ypes/lung-cancer/stages/stage-iv-lung- cancer (September 2021) [accessed December 30th 2021].
44. Ichsan M.I, et al. Hubungan Kadar Carcinoembryonic Antigen (CEA) dengan Subtipe Histologi Kanker Paru di RSUD Abdul Wahab Sjahranie Samarinda. Jurnal Kedokteran Mulawarman 2020;7(3): 23-30.
45. Zheng M. Classification and Pathology of Lung Cancer. Elsevier 2016; 25: 447-468.
46. Oktaviyanti I.K. Mutasi EGFR Pada Pemeriksaan Sitologi Adenokarsinoma Paru. Berkala Kedokteran 2015:11(2): 213-219.
47. Kumari N, et al. Epidermal Growth Factor Receptor Mutation Frequency in Squamous Cell Carcinoma and Its Diagnostic Performance in Cytological Samples: A Molecular and Immunohistochemical Study. World J Oncol 2019;10(3): 142-150.
Published
2022-06-30
How to Cite
KOSWARA, Teja; IRIAWAN, Jusron; SURYA, Fiona. KARAKTERISTIK KARSINOMA PARU BUKAN SEL KECIL DAN HASIL PEMERIKSAAN EGFR DI RSUP DR. HASAN SADIKIN PERIODE TAHUN 2018-2020. Medika Kartika : Jurnal Kedokteran dan Kesehatan, [S.l.], v. 5, n. 2, p. 150-161, june 2022. ISSN 2655-6537. Available at: <http://medikakartika.unjani.ac.id/medikakartika/index.php/mk/article/view/434>. Date accessed: 28 sep. 2022.